Dr. Claire Carlier

Diplômes

• DIU Echographie (2013)
• DIU de Carcinologie clinique à l’Institut Gustave Roussy (2018),
• DIU d’Immuno-oncologie à l’Institut Gustave Roussy (2019)
• DESC de cancérologie
• FMC d’Education thérapeutique.
• Master 1BSQ en oncogénétique (Dr DELVINCOURT, 2009)
• Master 2BSQR Effet anti-angiogénique tumoral du CD160, Pr BENSUSSAN, 2016
• Thèse de médecine : Effet anti-angiogénique tumoral du CD160 Pr Bensussan 2018
• DESC de cancérologie : Cours de chimiothérapie 2021ESMO Examination 2024

Cursus hospitalo-universitaire

• Internat de Médecine Générale à Reims avec DESC d’oncologie médicale: 1er semestre en Médecine Interneet Maladies Infectieuses, CHU de Reims, Pr Jaussaud 2e semestre aux Urgences, CHU deReims, Dr Carolet 3e semestre en Oncologie à l’Institut Jean Godinot, service Rubis, DrPrevost 4e semestre en Médecine Libérale, Dr Girardot (éducation thérapeutique) 5esemestre en Gynécologie, CHU de Reims (Pr Graeslin) 6e semestre en Soins Palliatifs,l’Institut Jean Godinot (Dr Dubroeucq). 2013-2017
• FFI en oncologie et Radiothérapie, Institut Godinot (PrMerrouche). 2016-2017
• Master 2 BSQR Reims. 2017
• Assistante en Oncologie partagée Godinot -CHU. 2017-2019
• Faisant Fonction de Praticien des centres delutte contre le cancer, partagée entre l’UMA-CH du CHU de Reims (PrBouché) et le Département D’Oncologie Médicale de l’InstitutGodinot (Pr Merrouche)cien des centres de lutte contre le cancer, partagée entre l’UMA-CH du CHU. 2019 à aujourd'hui

Fonctions institutionnelles

• Coordonateur RCP Oncodermatologie
• Coordonateur régionale RCP Tigre
• Référent grand Est Immunotoxicités
• Encadrement Master 1 et Thèses de médecine et pharmacie. RechercheCo-animatrice de la réunion hebdomadaire de recherche clinique en oncologie de l’UMA-CH du CHU de Reims. Investigatrice et co-investigatrice en Onco-dermatologie et Onco-hépatologie. Animatrice de la RCP d’onco-dermatologie de Godinot. Co-animatrice de la RCP TIGRE (Immunotoxicités).

Sociétés savantes et groupes coopérateurs

• ESMO, ASCO

Publications

10.1002/ueg2.12602 39118264 Brugel, M ; Callon, S ; Carlier, C ; Amroun, KL ; Botsen, D ; Kianmanesh, R & al 12 Association between pancreatic adenocarcinoma risk and concentration of organochlorine pesticides in adipose tissue and urine: A targeted-screening analysis case-control study (PESTIPAC). United European Gastroenterol J2050-6414      101606807  2024 {KI} 6 B 6  3 2 12 0,52173914    Journal Article   Essais SIGREC promotion interne "2020-A00339-30/CHU REIMS" NULL Oui  NCT04429490

10.1177/1078155224126973839090999 Perrier, M ; Zuccaro, E ; Carlier, C ; Brugel, M ; Slimano, F ; Bouché, O 6 Incidence of hand-foot syndrome with protein kinase inhibitors in advanced hepatocellular carcinoma patients who received atezolizumab-bevacizumab combination.J Oncol Pharm Pract  1477-092X 951137220241,07816E+16  {DM,TU}                      1,3 E  23 2  4  0,235294119  Journal Article 

10.1177/1078155223118713637437182 Le Bozec, A ; Guédon, M ; Brugel, M ; Laurent, M ; Carlier, C ; Hettler, D & al 11 Prevalence of cannabidiol (CBD) consumption and cancer patients'' expectations in one oncology day-hospital: A cross-sectional study and questionnaire validation. J Oncol Pharm Pract  1477-092X95113722023 1,07816E+16  {DM,TU}1,3 E  2 k1 2 0,090909094 Journal Article

10.1016/j.pan.2023.06.01037394294  Brugel, M ; Marulier, T ; Evrard, C ; Carlier, C ; Tougeron, D ; Piessen, G & al 13Genetic counselling referral practices for patients with pancreatic adenocarcinoma: A French retrospective multicentre observational cohort study (CAPANCOGEN). Pancreatology 1424-3911100966936202323622-629 {KI} Adenocarcinoma|Pancreatic Neoplasms3,6C4 k 14 0,166666672  Journal Article 

10.3389/fphar.2023.1137791 37274119 Le Bozec, A ; Brugel, M ; Djerada, Z ; Ayad, M ; Perrier, M ; Carlier, C & al 10 Beta-blocker exposure and survival outcomes in patients with advanced pancreatic ductal adenocarcinoma: a retrospective cohort study (BETAPANC). Front Pharmacol 1663-98121015489232023141137791  {TU}5,6B 6k160,285714291 Journal Article

10.1016/j.pan.2023.03.005   37037682 Brugel, M ; Dupont, M ; Carlier, C ; Botsen, D ; Essi, DE ; Sanchez, V & al 9 Association of palliative care management and survival after chemotherapy discontinuation in patients with advanced pancreatic adenocarcinoma: A retrospective single-centre observational study.  Pancreatology 1424-3911100966936 2023 23 403-410{KI}Adenocarcinoma|Neoplasms|Pancreatic Neoplasms3,6C432 8 0,400000006 Journal Article

10.1111/bcp.15701 36849134 Guedon, M ; Le Bozec, A ; Brugel, M ; Clarenne, J ; Carlier, C ; Perrier, M & al 11 Cannabidiol-drug interaction in cancer patients: A retrospective study in a real-life setting. Br J Clin Pharmacol 365-2125 7503323         2023 892322-2328{TU} Cannabidiol|Neoplasms 3,4C4k 140,181818187  Journal Article

10.1177/1758835922114853636643657  Callon, S ; Brugel, M ; Botsen, D ; Royer, B ; Slimano, F ; Feliu, C & al 15 Renal impairment and abnormal liver function tests in pre-therapeutic phenotype-based DPD deficiency screening using uracilemia: a comprehensive population-based study in 1138 patients.  Ther Adv Med Oncol  1758-8340 101510808202315 1,75884E+16 {DM} 4,9C 4 k 14 0,15384616 Journal Article

10.1186/s12885-022-10192-436434607 Dupont, M ; Carlier, C ; Gower-Rousseau, C ; Barbier-Lider, P ; Botsen, D ; Brasseur, M & al 19 Incidence and associated factors of cetuximab-induced hypersensitivity infusion reactions in 1392 cancer patients treated in four French areas: a possible association with Lyme disease?  BMC Cancer1471-2407100967800 202222 1219 {DM} Drug Hypersensitivity |Head and Neck Neoplasms| Lyme Disease 3,8 C 423120,400000006  Journal Article

10.3390/nu1421444836364711 Martin, P ; Botsen, D ; Brugel, M ; Bertin, E ; Carlier, C ; Mahmoudi, R & al   9  Association of Low Handgrip Strength with Chemotherapy Toxicity in Digestive Cancer Patients: A Comprehensive Observational Cohort Study (FIGHTDIGOTOX). Nutrients 2072-6643 101521595202214 {SA} Antineoplastic Agents|Gastrointestinal Neoplasms|Sarcopenia 5,9B  6k160,300000004  Journal Article

10.3390/pharmaceutics1410211936297556  Laures, N ; Konecki, C ; Brugel, M ; Giffard, AL ; Abdelli, N ; Botsen, D & al  12 Impact of Guidelines Regarding Dihydropyrimidine Dehydrogenase (DPD) Deficiency Screening Using Uracil-Based Phenotyping on the Reduction of Severe Side Effect of 5-Fluorouracil-Based Chemotherapy: A Propension Score Analysis. Pharmaceutics 1999-4923 101534003 2022 14  {TU} 5,4B 6k 160,26086957 Journal Article

10.1016/j.dld.2022.08.02336089524 Brugel, M ; Carlier, C ; Reyes-Castellanos, G ; Callon, S ; Carrier, A ; Bouché, O 6 Pesticides and pancreatic adenocarcinoma: A transversal epidemiological, environmental and mechanistic narrative review. Dig Liver Dis 1878-35621009583852022 541605-1613 {KI} Adenocarcinoma| Diabetes Mellitus, Type 2| Pancreatic Neoplasms|Pesticides 4,5C423120,70588237 Review 

10.1002/cam4.4817  35593199 Laurent, L ; Brugel, M ; Carlier, C ; Clere, F ; Bertrand, A ; Botsen, D & al 20 One-year COVID-19 outcomes on the oncology care patient pathway: Results of a French descriptive, cross-sectional comprehensive study (ONCOCARE-COV). Cancer Med    2045-7634101595310202211 4865-4879{DM} COVID-19|Neoplasms 4C43280,258064508 Journal Article

10.1016/j.ejca.2022.01.040  35259629 Brugel, M ; Letrillart, L ; Evrard, C ; Thierry, A ; Tougeron, D ; El Amrani, M & al 29 Impact of the COVID-19 pandemic on disease stage and treatment for patients with pancreatic adenocarcinoma: A French comprehensive multicentre ambispective observational cohort study (CAPANCOVID). Eur J Cancer 1879-085290053732022 166 8-20 {DM} Adenocarcinoma |COVID-19| Pancreatic Neoplasms 8,4B6ADA3 180,450000018 Journal Article. Essais SIGREC promotion interne "510000029_1035/CHU REIMS" NULLOui NCT04406571

10.1016/j.ejca.2020.09.03533129039 Lièvre, A ; Turpin, A ; Ray-Coquard, I ; Le Malicot, K ; Thariat, J ; Ahle, G & al28  Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19). Eur J Cancer 1879-0852 90053732020141 62-81 {DM} COVID-19 |Neoplasms 9,162 B6  Inv060 Journal Article 

10.1002/onco.13578 33111460 Brugel, M ; Carlier, C ; Essner, C ; Debreuve-Theresette, A ; Beck, MF ; Merrouche, Y & al  7  Dramatic Changes in Oncology Care Pathways During the COVID-19 Pandemic: The French ONCOCARE-COV Study.  Oncologist 549-490X 9607837 2021 26 e338-e341 {DM} COVID-19|Infection Control|Medical Oncology|Neoplasms|Pandemics 5,837 C423 120,666666687 Journal Article